Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. (Q54727171)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. (English)

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

1 reference

based on heuristic

inferred from title

Leishmania amazonensis

object named as

Leishmania amazonensis

1 reference

based on heuristic

inferred from title

Manuel Calvopiña

3

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

author name string

Armijos RX

1

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

Weigel MM

2

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

Hidalgo A

4

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

Cevallos W

5

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

Correa J

6

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

22

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

9-10

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

1320-1326

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

Leishmaniases of the New World: current concepts and implications for future research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Concentration of Pentostam in human breast milk

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

The traditional and conventional medical treatment of cutaneous leishmaniasis in rural Ecuador

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Vaccines against leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Further trials of a vaccine against American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

The epidemiology of cutaneous leishmaniasis in subtropical Ecuador

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Human cutaneous leishmaniasis in Ecuador: identification of parasites by enzyme electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Analyse chimiotaxonomique de vingt-deux souches deLeishmaniaisolées au nord-ouest de l'Équateur

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Recurrent lesions in human Leishmania braziliensis infection--reactivation or reinfection?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Gp63 gene polymorphism and population structure of Leishmania donovani complex: influence of the host selection pressure?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Identification of Mexican Leishmania species by analysis of PCR amplified DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.06.002

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2003.06.002

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

1 reference

Europe PubMed Central

3 June 2018

http://europepmc.org/abstract/MED/15003662

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54727171&oldid=1898980619"